Eli Lilly’s LY3819253 Antibody, the BLAZE-2 Study

BLAZE-2 is testing the LY3819253 antibody. It will be enrolling staff and residents in skilled nursing and assisted living facilities with a high risk of exposure to SARS-CoV-2. The study questions are:

  • Does the antibody prevent the acquisition of SARS-CoV-2?
  • Does the antibody help to prevent the development of more severe COVID-19, or does it reduce the symptoms?

The study will be conducted in the United States with up to 2,400 participants. LY3819253 is designed to bind to SARS‑CoV-2 and prevent the virus from entering healthy cells. LY3819253 was developed in a lab by the pharmaceutical company Eli Lilly. LY3819253 cannot give you SARS-CoV-2, nor will it make you sick with COVID-19.

Visit blaze2study.com or ClinicalTrials.gov - NCT04497987 for additional details about the Eli Lilly monoclonal antibody clinical study to prevent COVID-19. A Spanish version of the website is available at blaze2study.com/es-us. You may also call the BLAZE-2 Call Center at (800) 953-5234 or (718) 210-9713 from 9 a.m. to 5:30 p.m. Eastern Time Monday through Friday.

Interested in volunteering for a COVID-19 Prevention Clinical Study?

Selecting the button below will take you to the CoVPN Volunteer Screening Registry.

Volunteer Now!

Or register by calling 1-866-288-1919.